<DOC>
	<DOC>NCT00159081</DOC>
	<brief_summary>Prospective, randomized, double-blind, multi-center study on 1 year course and treatment outcome under low-dose typical (haloperidol) vs. atypical neuroleptics (risperidone) in first-episode schizophrenia.</brief_summary>
	<brief_title>One Year Drug Treatment in First-Episode Schizophrenia</brief_title>
	<detailed_description>The objective of this multi-center study is to optimize the long-term treatment of patients with first episode schizophrenia. This investigation should contribute to the issue of effective relapse prevention in first-episode patients. 1-year maintenance neuroleptic treatment is done with low dose haloperidol or risperidone (target dose 2-4 mg/die).</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>After the acute treatment of the firstepisode in schizophrenia (according ICD10 F20) Age between 18 and 55 Informed consent Residence outside of the catchment area Legal reasons Insufficient knowledge of the German language Substance abuse or addiction Pregnancy Serious physical illness Organic brain disease Contraindication to neuroleptic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>first episode</keyword>
	<keyword>long-term treatment</keyword>
	<keyword>typical vs. atypical neuroleptics</keyword>
</DOC>